Biotech Values

[DewDiligence]

The Norwegian government is helping to facilitate a Remicade FoB by running its own switching study:

http://www.biopharma-reporter.com/Markets-Regulations/Norway-to-facilitate-switch-to-biosimilars-with-3m-Remicade-study

I suspect we’ll see more of these kinds of government-funded FoB studies in various countries. The cost of running such a study pales in comparison to the potential savings from switching government-reimbursed patients from the original branded drug to the FoB.